Edition:
India

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

53.30USD
8:44pm IST
Change (% chg)

$0.83 (+1.58%)
Prev Close
$52.47
Open
$52.62
Day's High
$53.54
Day's Low
$52.37
Volume
10,570
Avg. Vol
148,032
52-wk High
$73.83
52-wk Low
$39.11

Latest Key Developments (Source: Significant Developments)

Emergent Biosolutions Receives EMA Prime Designation For Its Chikungunya Virus Vlp Vaccine Candidate
Thursday, 10 Oct 2019 

Oct 10 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS RECEIVES EMA PRIME DESIGNATION FOR ITS CHIKUNGUNYA VIRUS VLP VACCINE CANDIDATE.EMERGENT BIOSOLUTIONS INC - CONTEMPLATES INITIATION OF A PIVOTAL TRIAL FOR CHIKUNGUNYA VACCINE CANDIDATE IN 2020.  Full Article

Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000 Into the Strategic National Stockpile
Tuesday, 3 Sep 2019 

Sept 3 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS AWARDED 10-YEAR HHS CONTRACT TO DELIVER ACAM2000®, (SMALLPOX (VACCINIA) VACCINE, LIVE) INTO THE STRATEGIC NATIONAL STOCKPILE.EMERGENT BIOSOLUTIONS - CONTRACT AWARD VALUED AT ABOUT $2 BILLION OVER 10 YEARS FOR CONTINUED SUPPLY OF ACAM2000 INTO U.S. STRATEGIC NATIONAL STOCKPILE.EMERGENT BIOSOLUTIONS INC - COMPANY EXPECTS TO DELIVER INTO SNS A MAJORITY OF DOSES UNDER BASE YEAR BY YEAR END 2019.  Full Article

Emergent Biosolutions Reports Q1 Adjusted Loss Per Share $0.13
Friday, 3 May 2019 

May 2 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 ADJUSTED LOSS PER SHARE $0.13.Q1 LOSS PER SHARE $0.51.Q1 REVENUE $190.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $201.2 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.09 -- REFINITIV IBES DATA.SEES Q2 2019 REVENUE $200 MILLION TO $220 MILLION.PROVIDES Q2 2019 REVENUE FORECAST OF $200M-$220M.FOR FY 2019, COMPANY REAFFIRMS ITS EXPECTATION OF TOTAL REVENUES, NET INCOME, ADJUSTED NET INCOME, EBITDA, ADJUSTED EBITDA.Q2 REVENUE VIEW $254.1 MILLION -- REFINITIV IBES DATA.  Full Article

Emergent Biosolutions Reports Interim Results From Phase 2 Study Evaluating Its Chikungunya Virus Vaccine Candidate
Tuesday, 16 Apr 2019 

April 16 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES INTERIM RESULTS FROM PHASE 2 STUDY EVALUATING CHIKV-VLP, CHIKUNGUNYA VIRUS VACCINE CANDIDATE.EMERGENT BIOSOLUTIONS - UP TO 98% OF STUDY PARTICIPANTS PRODUCED A NEUTRALIZING ANTIBODY RESPONSE AGAINST CHIKUNGUNYA VIRUS (CHIKV) BY DAY 7.EMERGENT BIOSOLUTIONS INC - VACCINE CANDIDATE WAS WELL-TOLERATED ACROSS ALL STUDY ARMS.EMERGENT BIOSOLUTIONS INC - NO SIGNIFICANT VACCINE-RELATED SAFETY CONCERNS HAVE BEEN IDENTIFIED IN ANALYSES TO DATE.  Full Article

Emergent Biosolutions Awarded U.S. Department Of State Contract To Supply Medical Countermeasures For Chemical Warfare Agents
Friday, 1 Mar 2019 

Feb 28 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS AWARDED U.S. DEPARTMENT OF STATE CONTRACT TO SUPPLY MEDICAL COUNTERMEASURES FOR CHEMICAL WARFARE AGENTS.EMERGENT BIOSOLUTIONS INC - TOTAL CONTRACT VALUE OF A MINIMUM OF APPROXIMATELY $7 MILLION TO A MAXIMUM OF $100 MILLION OVER CONTRACT'S PERIOD OF PERFORMANCE.EMERGENT BIOSOLUTIONS INC - CONTRACT IS COMPRISED OF A FIVE-YEAR BASE PERIOD OF PERFORMANCE ALONG WITH FIVE ONE-YEAR OPTION PERIODS.  Full Article

Emergent Biosolutions Reports Fourth Quarter And Full Year 2018 Financial Results
Friday, 22 Feb 2019 

Feb 21 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $0.75.Q4 LOSS PER SHARE $0.07.Q4 REVENUE $270.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $270 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.65 -- REFINITIV IBES DATA.SEES Q1 2019 REVENUE $185 MILLION TO $205 MILLION.FOR FULL YEAR 2019, COMPANY REAFFIRMS ITS EXPECTATION.  Full Article

Emergent Biosolutions Announces Appointment Of Robert Kramer, Sr. To Its Board
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES APPOINTMENT OF ROBERT G. KRAMER, SR. TO ITS BOARD OF DIRECTORS.EMERGENT BIOSOLUTIONS -ROBERT KRAMER WILL ASSUME ROLE OF PRESIDENT AND CEO AND WILL SERVE ON THE EMERGENT BOARD, SUCCEEDING DANIEL J. ABDUN-NABI.EMERGENT BIOSOLUTIONS INC SAYS ROBERT KRAMER WILL ASSUME ROLE OF PRESIDENT AND CEO EFFECTIVE APRIL 1, 2019.  Full Article

Emergent BioSolutions Says Robert Kramer's Annual Base Salary Will Rise To $700,000 Upon His Starting As CEO
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS INC - KRAMER'S ANNUAL BASE SALARY WILL RISE TO $700,000 UPON HIS COMMENCING SERVICE AS CHIEF EXECUTIVE OFFICER.  Full Article

Emergent Biosolutions Says Daniel Abdun-Nabi To Retire As CEO
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES DANIEL J. ABDUN-NABI TO RETIRE AS CEO; ROBERT G. KRAMER, SR. TO BECOME PRESIDENT AND CEO.EMERGENT BIOSOLUTIONS INC - ABDUN-NABI HAS ALSO INDICATED THAT HE PLANS TO STEP DOWN AS A MEMBER OF EMERGENT BOARD.EMERGENT BIOSOLUTIONS - EXPECTS BOARD TO APPOINT KRAMER TO FILL BOARD VACANCY CREATED BY ABDUN-NABI'S RETIREMENT.  Full Article

Emergent Biosolutions Announces Submission To FDA Of Application Covering Emergency Use Authorization For Nuthrax™
Friday, 28 Dec 2018 

Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES SUBMISSION TO FDA OF APPLICATION COVERING EMERGENCY USE AUTHORIZATION FOR NUTHRAX™.EMERGENT BIOSOLUTIONS INC - SUBMISSION IS ANTICIPATED TO UNDERGO REVIEW BY FDA THROUGH FIRST HALF OF 2019..  Full Article